European Medicines Agency decision
P/0239/2013

of 24 September 2013


Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0239/2013

of 24 September 2013


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency’s decision P/0024/2012 issued on 27 January 2012,

Having regard to the application submitted by GlaxoSmithKline Trading Service Limited on 14 May 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 August 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for dabrafenib (mesilate), capsule, hard, powder for oral suspension, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

This decision is addressed to GlaxoSmithKline Trading Service Limited, 6900 Cork Airport Business Park, Kinsale Road, County Cork, Ireland.

Done at London, 24 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan
EMEA-001147-PIP01-11-M01

Scope of the application

Active substance(s):
Dabrafenib (mesilate)

Condition(s):
Treatment of melanoma
Treatment of solid malignant tumours (excluding melanoma)

Pharmaceutical form(s):
Capsule, hard
Powder for oral suspension

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
GlaxoSmithKline Trading Service Limited

Basis for opinion


The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 June 2013.

Scope of the modification

A measure has been added and the timelines of the Paediatric Investigation Plan have been modified.
Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 9 August 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

1.1. Condition: treatment of solid malignant tumours (excluding melanoma)

The waiver applies to:

- preterm and term newborn infants from birth to less than 28 days;
- for capsules, hard, for oral use, and for powder for oral suspension, for oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not normally occur in the specified paediatric subsets.

2. Paediatric Investigation Plan

2.1. Condition: treatment of melanoma

2.1.1. Indication(s) targeted by the PIP

Treatment of adolescent patients with melanoma containing BRAF V600 activating mutations.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Capsule, hard.

Powder for oral suspension.

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>1</td>
<td>Measure 1 Development of an age-appropriate powder for oral suspension formulation.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>2</td>
<td>Measure 2 Dose range / tolerability juvenile rat toxicity study to evaluate toxicokinetics and clinical observations in rats given dabrafenib or vehicle control.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Measure 3 Definitive juvenile rat toxicity study to evaluate toxicokinetics, clinical observations, laboratory parameters and histopathology of major organs in rats given dabrafenib (at doses determined in measure 2) or vehicle control.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Measure 8 Juvenile rat renal toxicity study.</td>
</tr>
<tr>
<td>Area</td>
<td>Number of studies</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Clinical     | 4                 | **Measure 4**  
Open-label, single agent, uncontrolled dose escalation trial to determine the safety, tolerability, pharmacokinetics and maximum tolerated dose of dabrafenib in children from 1 month to less than 18 years of age with advanced BRAF V600-mutant solid tumours.  
**Measure 6**  
Trial to evaluate the relative bioavailability of dabrafenib pharmaceutical forms in adults.  
**Measure 7**  
Measure to demonstrate that the pharmacokinetics, pharmacodynamics and efficacy of dabrafenib in adolescent patients (aged from 12 to less than 18 years of age) with BRAF V600-mutant melanoma are similar to that in adults with BRAF V600-mutant melanoma, using a modelling and simulation approach for the purpose of extrapolation. |

2.2. **Condition: treatment of solid malignant tumours (excluding melanoma)**

2.2.1. **Indication(s) targeted by the PIP**

Treatment of paediatric patients with solid malignant tumours containing BRAF V600 activating mutations.

2.2.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From 1 month to less than 18 years of age.

2.2.3. **Pharmaceutical form(s)**

Capsule, hard  
Powder for oral suspension

2.2.4. **Measures**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
</table>
| Quality      | 1                 | **Measure 1**  
As for condition "Treatment of melanoma".  
**Measure 2**  
As for condition "Treatment of melanoma". |
| Non-clinical | 2                 | **Measure 2**  
As for condition "Treatment of melanoma". |
<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
</table>
|             |                   | **Measure 3**  
As for condition "Treatment of melanoma".                                                                                               |
|             |                   | **Measure 8**  
As for condition "Treatment of melanoma".                                                                                               |
| Clinical    | 3                 | **Measure 4**  
As for condition "Treatment of melanoma".                                                                                               |
|             |                   | **Measure 5**  
Open-label, randomised controlled parallel-group trial to determine the safety and efficacy of dabrafenib in children from 1 month to less than 18 years of age with advanced BRAF V600-mutant solid tumours excluding melanoma (specific tumour type to be decided based on the results of measure 4). |
|             |                   | **Measure 6**  
As for condition "Treatment of melanoma".                                                                                               |

### 3. Follow-up, completion and deferral of PIP

| Concerns on potential long term safety and efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By July 2019 |
| Deferral for one or more studies contained in the paediatric investigation plan: | Yes |